Induced sputum biomarkers for monitoring cystic fibrosis lung disease

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 9, 2012, Pages 812-814

  Trapnell, Bruce C ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; GELATINASE A; GELATINASE B; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; MYELOPEROXIDASE; PROTEIN NE ALPHA 1; PROTEIN NEAPC; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CYSTIC FIBROSIS; DISEASE EXACERBATION; EDITORIAL; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MONITORING; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS;

CYSTIC FIBROSIS; FEMALE; HUMANS; INFLAMMATION; LUNG; MALE; SPUTUM;

EID: 84868298317     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201209-1731ED     Document Type: Editorial

References (14)

1. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Valle D, Sly WS, eds. The metabolic and molecular basis of inherited disease, 8th ed. New York: McGraw Hill; 2001. pp. 521-588.
2. Cystic Fibrosis Mutation Database [updated 2011 Apr 25; accessed 2012 Sep 10]. Available from: http://www.genet.sickkids.on.ca/cftr/
3. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005;353:1443-1453.
4. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-454.
5. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001;164:1425-1431.
6. Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JF Jr, Dearborn DG. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985;132:529-535.
7. Stone PJ, Konstan MW, Berger M, Dorkin HL, Franzblau C, Snider GL. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med 1995;152:157-162.
8. Sagel SD, Sontag MK, Wagener JS, Kapsner RK, Osberg I, Accurso FJ. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr 2002;141:811-817.
9. Sagel SD, Kapsner RK, Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2005;39:224-232.
10. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW. Association between pul-monary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007;175:822-828.
11. Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012;186:857-865.
12. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136.
13. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Doring G, van Koningsbruggen S, et al. Effect of treat-ment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719-725.
14. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337:392-394.